rewirebio.iobenchmarks
Dataset

Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort

121 BRCA1/BRCA2 variants of uncertain significance from 120 patients, tracked through successive reclassification steps. Aggregate counts only; the source's single gene-split reclassification-rate sentence cannot be reconciled against its own Methods denominators and is not used in this intake (see research notes).

Evaluation results

2 evaluations · 4 results. Different protocols are not a single leaderboard.

Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: ACMG/AMP classification system with SVI recommendations (t2)Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2)
Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
24 Count (reclassified: VUS to likely benign)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Benet-Pages t2 (ACMG/AMP + SVI) reclassification of the 121-variant VUS cohort

Not reported

Aggregation: Not reported

Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)": "Of 121 VUS, 20% (n = 24) were reclassified as LB..."
Configuration: ACMG/AMP classification system with SVI recommendations (t2)Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2)
Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
20% Proportion (reclassified: VUS to likely benign)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Benet-Pages t2 (ACMG/AMP + SVI) reclassification of the 121-variant VUS cohort

Not reported

Aggregation: Not reported

Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)": "Of 121 VUS, 20% (n = 24) were reclassified as LB..."
Configuration: ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 (t3)Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ENIGMA VCEP step (t3)
Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
101 Count (reclassified: VUS to benign or likely benign)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Benet-Pages t3 (ENIGMA VCEP) reclassification of the 121-variant VUS cohort

Not reported

Aggregation: Not reported

Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ENIGMA specifications (ENIGMA VCEP)": "...83.5% (n = 101) of VUS were reclassified as B (n = 9) or LB (n = 92) (Figure 2A; t3)."
Configuration: ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 (t3)Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ENIGMA VCEP step (t3)
Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
83.5% Proportion (reclassified: VUS to benign or likely benign)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Benet-Pages t3 (ENIGMA VCEP) reclassification of the 121-variant VUS cohort

Not reported

Aggregation: Not reported

Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ENIGMA specifications (ENIGMA VCEP)": "...83.5% (n = 101) of VUS were reclassified as B (n = 9) or LB (n = 92) (Figure 2A; t3)."

Source checking is not independent reproduction. Release 2026-11-21-adc15377fab2.

Research readiness

0 of 4 readiness checks met. These checks assess whether the evidence supports a reproducible investigation; a source-checked score alone does not meet them.

Readiness checks, gaps and artifacts

Release 2026-11-21-adc15377fab2 · Evidence verified: Not verified

Evidence incomplete

Replay metrics

Exact outcomes, predictions, identifiers and evaluator are connected.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Metrics are recomputed from the saved predictions: not yet verified

Verified: Not verified

Evidence incomplete

Investigate discrepancies

Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Metrics are recomputed from the saved predictions: not yet verified
  • Sample annotations are recorded: not yet verified
  • Dependence between samples is assessed: not yet verified

Verified: Not verified

Evidence incomplete

Run locally

A pinned recipe describes the inputs, environment and resource requirements.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • A pinned run recipe exists: not yet verified
  • Compute requirements are estimated: not yet verified

Verified: Not verified

Evidence incomplete

Validate independently

Separate data and exposure records support an independent test.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Independent validation data exist: not yet verified
  • Overlap with training data is checked: not yet verified

Verified: Not verified

Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.

Artifacts and reproduction

No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.

Dataset and evaluation context

A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

5 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-adc15377fab2
Property and statementOriginal source and locationReview and provenance
Patient count
120
Context-only references
Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system

Original source ↗

Materials and Methods, "Patients and variant data"

Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied
Retrieved: 2026-10-05T14:02:27Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.patient_count

Source artifact SHA-256: 2e458cacad35cca0507753c43c5104b75217593a0c2fdbd16143f0391fba33eb

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Source location
Materials and Methods, "Patients and variant data"
Context-only references
Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system

Original source ↗

Materials and Methods, "Patients and variant data"

Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied
Retrieved: 2026-10-05T14:02:27Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.source_locator

Source artifact SHA-256: 2e458cacad35cca0507753c43c5104b75217593a0c2fdbd16143f0391fba33eb

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Total vus count
121
Context-only references
Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system

Original source ↗

Materials and Methods, "Patients and variant data"

Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied
Retrieved: 2026-10-05T14:02:27Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.total_vus_count

Source artifact SHA-256: 2e458cacad35cca0507753c43c5104b75217593a0c2fdbd16143f0391fba33eb

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Description
121 BRCA1/BRCA2 variants of uncertain significance from 120 patients, tracked through successive reclassification steps. Aggregate counts only; the source's single gene-split reclassification-rate sentence cannot be reconciled against its own Methods denominators and is not used in this intake (see research notes).
Context-only references
Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system

Original source ↗

Materials and Methods, "Patients and variant data"

Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied
Retrieved: 2026-10-05T14:02:27Z

not individually reviewed

No individual claim review recorded

Audit details

Field: description

Source artifact SHA-256: 2e458cacad35cca0507753c43c5104b75217593a0c2fdbd16143f0391fba33eb

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Name
Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
Context-only references
Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system

Original source ↗

Materials and Methods, "Patients and variant data"

Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied
Retrieved: 2026-10-05T14:02:27Z

not individually reviewed

No individual claim review recorded

Audit details

Field: name

Source artifact SHA-256: 2e458cacad35cca0507753c43c5104b75217593a0c2fdbd16143f0391fba33eb

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Sources and history

Release 2026-11-21-adc15377fab2 · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID uc-clinical-20261005-benet-pages-cohort.

Source locator: Materials and Methods, "Patients and variant data"

Related records

Suggest a correction